Filing Details
- Accession Number:
- 0001225208-25-001686
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-13 16:32:50
- Reporting Period:
- 2025-02-11
- Filing Date:
- 2025-02-13
- Accepted Time:
- 2025-02-13 16:32:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
885725 | Boston Scientific Corp | BSX | Surgical & Medical Instruments & Apparatus (3841) | 042695240 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1629277 | Bradley John Sorenson | 300 Boston Scientific Way Marlborough MA 01752-1234 | Evp, Global Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-02-11 | 10,182 | $0.00 | 36,631 | No | 4 | A | Direct | |
Common Stock | Disposition | 2025-02-11 | 3,793 | $105.98 | 32,838 | No | 4 | F | Direct | |
Common Stock | Disposition | 2025-02-12 | 2,156 | $0.00 | 30,682 | No | 4 | G | Direct | |
Common Stock | Disposition | 2025-02-12 | 6,389 | $105.06 | 24,293 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | G | Direct | |
No | 4 | S | Direct |
Footnotes
- On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
- Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.81 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.